Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Drug-induced hepatotoxicity (DIH) is a common adverse event that is associated with both antiretroviral (ARV) and anti-tuberculosis drugs (ATD). Moreover, the genetic variations predisposing ARV- and ARV-ATD-induced liver toxicity in African populations are not well investigated, despite the two diseases being the major global health problems in sub-Saharan Africa. We performed a genome-wide association study (GWAS) and replication study to identify the genetic variants linked to the risk of developing DIH due to ARV drugs alone, and ARV-ATD co-treatment in Ethiopian HIV-positive patients. Treatment-naïve newly diagnosed HIV patients (n = 719) with or without tuberculosis (TB) co-infection were enrolled prospectively and received efavirenz-based ARV therapy with or without rifampicin-based short course ATD, respectively. Whole-genome genotyping was performed by using the Illumina Omni Express Exome Bead Chip genotyping array with 951,117 single nucleotide polymorphisms (SNPs) on a total of 41 cases of DIH, and 452 people without DIH (treatment tolerants). The replication study was carried out for 100 SNPs with the lowest p-values (top SNPs) by using an independent cohort consisting of 18 DIH cases and 208 treatment tolerants. We identified a missense SNP rs199650082 (2756G→A, R919Q, p = 1.4 × 10-6, odds ratio [OR] = 18.2, 95% confidence interval [CI] = 7.1-46.9) in an endoplasmic reticulum to the nucleus signaling-1 (ERN1) gene on chromosome 17 to be associated with DIH in the ARV-only cohort. In the ARV-ATD co-treatment groups, rs4842407, a long intergenic noncoding RNAs (lincRNAs) transcript variant on chromosome 12, was associated with DIH (p = 5.3 × 10-7, OR = 5.4, 95% CI = 2.8-10.3). These genetic variants that are putatively associated with DIH due to ARV drugs alone and ARV-ATD co-treatment establish a foundation for future personalized medicine in people with HIV and TB and call for larger studies in independent populations.

[1]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[2]  M Ingelman-Sundberg,et al.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  H. Ellinger-Ziegelbauer,et al.  Direct Activation of the Stress-activated Protein Kinase (SAPK) and Extracellular Signal-regulated Protein Kinase (ERK) Pathways by an Inducible Mitogen-activated Protein Kinase/ERK Kinase Kinase 3 (MEKK) Derivative* , 1997, The Journal of Biological Chemistry.

[4]  R. Kaufman,et al.  A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. , 1998, Genes & development.

[5]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[6]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[7]  J. Neaton,et al.  Grade 4 Events Are as Important as AIDS Events in the Era of HAART , 2003, Journal of acquired immune deficiency syndromes.

[8]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[9]  J. Haines,et al.  Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[11]  U. Walker.  Antiretroviral therapy-induced liver alterations , 2007, Current opinion in HIV and AIDS.

[12]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[13]  Manuel A. R. Ferreira,et al.  Practical aspects of imputation-driven meta-analysis of genome-wide association studies. , 2008, Human molecular genetics.

[14]  S. Tishkoff,et al.  African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. , 2008, Annual review of genomics and human genetics.

[15]  A. Aseffa,et al.  Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients , 2008, PloS one.

[16]  M. Rela,et al.  A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. , 2009, The Journal of antimicrobial chemotherapy.

[17]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[18]  J. Downing,et al.  Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia , 2009, Proceedings of the National Academy of Sciences.

[19]  A. Daly.  Drug-induced liver injury: past, present and future. , 2010, Pharmacogenomics.

[20]  M. Núñez,et al.  Clinical syndromes and consequences of antiretroviral‐related hepatotoxicity , 2010, Hepatology.

[21]  D. Kwiatkowski,et al.  Methodological challenges of genome-wide association analysis in Africa , 2010, Nature Reviews Genetics.

[22]  L. Lindquist,et al.  Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients , 2011, PloS one.

[23]  U. Diczfalusy,et al.  Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians , 2011, The Pharmacogenomics Journal.

[24]  M. Molokhia,et al.  Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.

[25]  M. Núñez,et al.  Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy , 2011, Journal of the International Association of Physicians in AIDS Care.

[26]  M. Núñez,et al.  Liver Toxicity of Antiretroviral Drugs , 2012, Seminars in Liver Disease.

[27]  L. Lindquist,et al.  Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania , 2012, PloS one.

[28]  W. Haefeli,et al.  High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study , 2011, The Pharmacogenomics Journal.

[29]  E. Mariman,et al.  Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[30]  L. Bertilsson,et al.  Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations , 2013, PloS one.

[31]  M. Hudson,et al.  Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  A. Thompson,et al.  Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1α , 2014, BMC Biochemistry.

[33]  E. Bloch,et al.  Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring , 2013, International journal of STD & AIDS.

[34]  Xuefei Shi,et al.  Long non-coding RNAs: a new frontier in the study of human diseases. , 2013, Cancer letters.

[35]  M. Ingelman-Sundberg,et al.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. , 2014, Omics : a journal of integrative biology.

[36]  Lei Guo,et al.  Endoplasmic Reticulum Stress in Drug- and Environmental Toxicant-Induced Liver Toxicity , 2014, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[37]  C. Royal,et al.  Genome-Wide Association Studies in Africans and African Americans: Expanding the Framework of the Genomics of Human Traits and Disease , 2014, Public Health Genomics.

[38]  I. Schuppe-Koistinen,et al.  Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients , 2014, PloS one.

[39]  P. Watkins,et al.  Keratin‐18 and microRNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[40]  Yi-Shin Huang.  Recent progress in genetic variation and risk of antituberculosis drug‐induced liver injury , 2014, Journal of the Chinese Medical Association : JCMA.

[41]  Y. Xu,et al.  Cab45S inhibits the ER stress-induced IRE1-JNK pathway and apoptosis via GRP78/BiP , 2014, Cell Death and Disease.

[42]  G. Aithal,et al.  Genetic Basis of Drug-Induced Liver Injury: Present and Future , 2014, Seminars in Liver Disease.

[43]  R. Fontana,et al.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. , 2014, Gastroenterology.

[44]  Taotao Ma,et al.  Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. , 2014, Biochimica et biophysica acta.

[45]  T. Yamazaki,et al.  Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression , 2015, Molecular Cancer.

[46]  H. Yoon,et al.  Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis , 2014, Allergy, asthma & immunology research.

[47]  D. Waxman,et al.  Hepatic Long Intergenic Noncoding RNAs: High Promoter Conservation and Dynamic, Sex-Dependent Transcriptional Regulation by Growth Hormone , 2015, Molecular and Cellular Biology.

[48]  J. Grove,et al.  Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis , 2015, Seminars in Liver Disease.

[49]  Jianjian Zheng,et al.  lincRNA‐p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21 , 2015, The FEBS journal.

[50]  M. Kubo,et al.  Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma , 2015, PloS one.

[51]  M. Lee,et al.  Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity , 2016, BMC Genomics.

[52]  C. Masimirembwa,et al.  Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. , 2016, Omics : a journal of integrative biology.

[53]  D. B. Miranda-Filho,et al.  Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS , 2016, PloS one.

[54]  Guoliang Li,et al.  A Comprehensive Characterization of the Function of LincRNAs in Transcriptional Regulation Through Long-Range Chromatin Interactions , 2016, Scientific Reports.

[55]  W. Amogne,et al.  SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. , 2016, Omics : a journal of integrative biology.

[56]  Bicheng Chen,et al.  Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis , 2016, Mediators of inflammation.

[57]  J. Lindberg,et al.  Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury , 2016, Liver international : official journal of the International Association for the Study of the Liver.